R&G PharmaStudies Balance Sheet Health
Financial Health criteria checks 5/6
R&G PharmaStudies has a total shareholder equity of CN¥1.8B and total debt of CN¥33.1M, which brings its debt-to-equity ratio to 1.8%. Its total assets and total liabilities are CN¥2.2B and CN¥435.7M respectively. R&G PharmaStudies's EBIT is CN¥113.9M making its interest coverage ratio -5.1. It has cash and short-term investments of CN¥1.7B.
Key information
1.8%
Debt to equity ratio
CN¥33.14m
Debt
| Interest coverage ratio | -5.1x |
| Cash | CN¥1.70b |
| Equity | CN¥1.81b |
| Total liabilities | CN¥435.70m |
| Total assets | CN¥2.24b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 301333's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥374.4M).
Long Term Liabilities: 301333's short term assets (CN¥2.0B) exceed its long term liabilities (CN¥61.3M).
Debt to Equity History and Analysis
Debt Level: 301333 has more cash than its total debt.
Reducing Debt: 301333's debt to equity ratio has increased from 0% to 1.8% over the past 5 years.
Debt Coverage: 301333's debt is well covered by operating cash flow (637.3%).
Interest Coverage: 301333 earns more interest than it pays, so coverage of interest payments is not a concern.